A Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one year.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : imatinib
  • drug : Bosutinib

Phase: Phase 3

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Cytogenetic diagnosis of chronic phase Ph+ CML diagnosed less than 6 months. - Diagnosis of CML chronic phase confirmed. - Adequate hepatic and renal function. - Able to take oral tablets.

External Links

Explore related trials

Contact information

Primary Contact:

Michelle Takahashi 6507364032

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: